10 research outputs found
Transcriptome-based identification of PDGFA as a candidate secreted biomarker for hepatocellular carcinoma
Aim. Identification of candidate secreted biomarkers for hepatocellular carcinoma (HCC) diagnosis. Methods. Genes upregulated in HCC tissue and encoding secreted proteins were identified by RNA-seq. Gene expression changes in HCC were evaluated by RT-qPCR and meta-analysis of public databases. Biomarker properties were studied using ROC-curves, correlation and survival analysis. Results. PDGFA was identified by RNA-seq as an overexpressed gene encoding for a secreted protein in 5 HCC cases. PDGFA and GPC3 up-regulation was revealed in 17 of 19 HCC samples and in most cases from the public databases. Combination of PDGFA and GPC3 discerned HCC and non-tumor tissue better than PDGFA or GPC3 alone. PDGFA overexpression was associated with better overall survival of the patients at early HCC stage and with weaker tumor invasion into blood vessels. Conclusion. PDGFA is a valuable secreted biomarker for HCC that might be used in combination with GPC3 to increase its sensitivity.ΠΠ΅ΡΠ°. ΠΠ΄Π΅Π½ΡΠΈΡΠΊΠ°ΡΡΡ ΠΏΠΎΡΠ΅Π½ΡΡΠΉΠ½ΠΈΡ
Π±ΡΠΎΠΌΠ°ΡΠΊΠ΅ΡΡΠ², ΡΠΎ ΡΠ΅ΠΊΡΠ΅ΡΡΡΡΡΡΡ Π΄Π»Ρ Π΄ΡΠ°Π³Π½ΠΎΡΡΠΈΠΊΠΈ Π³Π΅ΠΏΠ°ΡΠΎΡΠ΅Π»ΡΠ»ΡΡΠ½ΠΎΡ ΠΊΠ°ΡΡΠΈΠ½ΠΎΠΌΠΈ (ΠΠ). ΠΠ΅ΡΠΎΠ΄ΠΈ. ΠΠ΅Π½ΠΈ, Π΅ΠΊΡΠΏΡΠ΅ΡΡΡ ΡΠΊΠΈΡ
ΠΏΡΠ΄Π²ΠΈΡΠ΅Π½Π° Π² ΡΠΊΠ°Π½ΠΈΠ½Ρ ΠΠ Ρ ΡΠΊΡ ΠΊΠΎΠ΄ΡΡΡΡ Π±ΡΠ»ΠΊΠΈ, ΡΠΎ ΡΠ΅ΠΊΡΠ΅ΡΡΡΡΡΡΡ, Π²ΠΈΡΠ²Π»ΡΠ»ΠΈ Π ΠΠ-ΡΠ΅ΠΊΠ²Π΅Π½ΡΠ²Π°Π½Π½ΡΠΌ. ΠΠΊΡΠΏΡΠ΅ΡΡΡ Π³Π΅Π½ΡΠ² ΠΎΡΡΠ½ΡΠ²Π°Π»ΠΈ ΠΠ’-ΠΠΠ Π°Π±ΠΎ Π²ΠΈΠΊΠΎΡΠΈΡΡΠΎΠ²ΡΠ²Π°Π»ΠΈ ΡΠ½ΡΠΎΡΠΌΠ°ΡΡΡ Π· Π²ΡΠ΄ΠΊΡΠΈΡΠΈΡ
Π±Π°Π· Π΄Π°Π½ΠΈΡ
. ΠΡΠΎΠΌΠ°ΡΠΊΠ΅ΡΠ½Ρ Π²Π»Π°ΡΡΠΈΠ²ΠΎΡΡΡ ΠΎΡΡΠ½ΡΠ²Π°Π»ΠΈ Π·Π° Π΄ΠΎΠΏΠΎΠΌΠΎΠ³ΠΎΡ ROC-ΠΊΡΠΈΠ²ΠΈΡ
, Π°Π½Π°Π»ΡΠ·Ρ ΠΊΠΎΡΠ΅Π»ΡΡΡΠΉ Ρ Π²ΠΈΠΆΠΈΠ²Π°Π½Π½Ρ. Π Π΅Π·ΡΠ»ΡΡΠ°ΡΠΈ. Π ΠΠ-ΡΠ΅ΠΊΠ²Π΅Π½ΡΠ²Π°Π½Π½Ρ ΠΏβΡΡΠΈ Π²ΠΈΠΏΠ°Π΄ΠΊΡΠ² ΠΠ Π²ΠΈΡΠ²ΠΈΠ»ΠΎ Π³ΡΠΏΠ΅ΡΠ΅ΠΊΡΠΏΡΠ΅ΡΡΡ PDGFA, ΡΠΎ ΠΊΠΎΠ΄ΡΡ ΡΠ΅ΠΊΡΠ΅ΡΡΡΠΌΠΈΠΉ Π±ΡΠ»ΠΎΠΊ. ΠΡΠ΄Π²ΠΈΡΠ΅Π½Π½Ρ Π΅ΠΊΡΠΏΡΠ΅ΡΡΡ PDGFA ΡΠ° GPC3 Π²ΠΈΡΠ²Π»Π΅Π½ΠΎ Π² 17 Π· 19 Π·ΡΠ°Π·ΠΊΡΠ² ΠΠ ΡΠ° Π΄Π»Ρ Π±ΡΠ»ΡΡΠΎΠ³ΠΎ Π²ΠΈΠΏΠ°Π΄ΠΊΡ Π·ΡΠ°Π·ΠΊΡΠ² Ρ Π±Π°Π·Π°Ρ
Π΄Π°Π½ΠΈΡ
. Π‘ΠΏΡΠ»ΡΠ½Π΅ Π²ΠΈΠΊΠΎΡΠΈΡΡΠ°Π½Π½Ρ PDGFA ΡΠ° GPC3 Π΄ΠΎΠ·Π²ΠΎΠ»ΡΡ ΡΠΎΡΠ½ΡΡΠ΅ Π²ΡΠ΄ΡΡΠ·Π½ΠΈΡΠΈ ΠΠ Π²ΡΠ΄ Π½Π΅ΠΏΡΡ
Π»ΠΈΠ½Π½ΠΎΡ ΡΠΊΠ°Π½ΠΈΠ½ΠΈ ΠΏΠ΅ΡΡΠ½ΠΊΠΈ , Π½ΡΠΆ PDGFA Π°Π±ΠΎ GPC3 ΠΎΠΊΡΠ΅ΠΌΠΎ. ΠΡΠΏΠ΅ΡΠ΅ΠΊΡΠΏΡΠ΅ΡΡΡ PDGFA Π°ΡΠΎΡΡΠΉΠΎΠ²Π°Π½Π° Π· ΠΊΡΠ°ΡΠΈΠΌ ΠΏΡΠΎΠ³Π½ΠΎΠ·ΠΎΠΌ Π΄Π»Ρ ΠΏΠ°ΡΡΡΠ½ΡΡΠ² Π· ΡΠ°Π½Π½ΡΠΌΠΈ ΡΡΠ°Π΄ΡΡΠΌΠΈ ΠΠ Ρ Π½ΠΈΠ·ΡΠΊΠΎΡ ΡΠ½Π²Π°Π·ΡΡΡ ΠΏΡΡ
Π»ΠΈΠ½ΠΈ Π² ΡΡΠ΄ΠΈΠ½ΠΈ. ΠΠΈΡΠ½ΠΎΠ²ΠΊΠΈ. PDGFA β ΠΏΠ΅ΡΡΠΏΠ΅ΠΊΡΠΈΠ²Π½ΠΈΠΉ Π±ΡΠΎΠΌΠ°ΡΠΊΠ΅Ρ ΠΠ, ΡΠΎ ΡΠ΅ΠΊΡΠ΅ΡΡΡΡΡΡΡ, ΡΠΊΠΈΠΉ ΠΌΠΎΠΆΠ΅ Π±ΡΡΠΈ Π²ΠΈΠΊΠΎΡΠΈΡΡΠ°Π½ΠΈΠΉ ΡΠ°Π·ΠΎΠΌ Π· GPC3 Π΄Π»Ρ ΠΏΡΠ΄Π²ΠΈΡΠ΅Π½Π½Ρ ΠΉΠΎΠ³ΠΎ ΡΡΡΠ»ΠΈΠ²ΠΎΡΡΡ.Π¦Π΅Π»Ρ. ΠΠΎΠΈΡΠΊ ΠΏΠΎΡΠ΅Π½ΡΠΈΠ°Π»ΡΠ½ΡΡ
ΡΠ΅ΠΊΡΠ΅ΡΠΈΡΡΠ΅ΠΌΡΡ
Π±ΠΈΠΎΠΌΠ°ΡΠΊΠ΅ΡΠΎΠ² Π΄Π»Ρ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠΈ Π³Π΅ΠΏΠ°ΡΠΎΡΠ΅Π»Π»ΡΠ»ΡΡΠ½ΠΎΠΉ ΠΊΠ°ΡΡΠΈΠ½ΠΎΠΌΡ (ΠΠ). ΠΠ΅ΡΠΎΠ΄Ρ. ΠΠ΅Π½Ρ, ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΡ ΠΊΠΎΡΠΎΡΡΡ
ΠΏΠΎΠ²ΡΡΠ΅Π½Π° Π² ΡΠΊΠ°Π½ΠΈ ΠΠ ΠΈ ΠΊΠΎΠ΄ΠΈΡΡΡΡΠΈΠ΅ ΡΠ΅ΠΊΡΠ΅ΡΠΈΡΡΠ΅ΠΌΡΠ΅ Π±Π΅Π»ΠΊΠΈ, Π²ΡΡΠ²Π»ΡΠ»ΠΈ Π ΠΠ-ΡΠ΅ΠΊΠ²Π΅Π½ΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ. ΠΠΊΡΠΏΡΠ΅ΡΡΠΈΡ Π³Π΅Π½ΠΎΠ² ΠΎΡΠ΅Π½ΠΈΠ²Π°Π»ΠΈ ΠΠ’-ΠΠ¦Π ΠΈΠ»ΠΈ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π»ΠΈ ΠΈΠ½ΡΠΎΡΠΌΠ°ΡΠΈΡ ΠΈΠ· ΠΎΡΠΊΡΡΡΡΡ
Π±Π°Π· Π΄Π°Π½Π½ΡΡ
. ΠΠΈΠΎΠΌΠ°ΡΠΊΠ΅ΡΠ½ΡΠ΅ ΡΠ²ΠΎΠΉΡΡΠ²Π° ΠΎΡΠ΅Π½ΠΈΠ²Π°Π»ΠΈ Ρ ΠΏΠΎΠΌΠΎ-ΡΡΡ ROC-ΠΊΡΠΈΠ²ΡΡ
, Π°Π½Π°Π»ΠΈΠ·Π° ΠΊΠΎΡΡΠ΅Π»ΡΡΠΈΠΉ ΠΈ Π²ΡΠΆΠΈΠ²Π°Π΅ΠΌΠΎΡΡΠΈ. Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. Π ΠΠ-ΡΠ΅ΠΊΠ²Π΅Π½ΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ 5 ΡΠ»ΡΡΠ°Π΅Π² ΠΠ Π²ΡΡΠ²ΠΈΠ»ΠΎ Π³ΠΈΠΏΠ΅ΡΡΠΊΡΠΏΡΠ΅Ρ-ΡΠΈΡ PDGFA, ΠΊΠΎΠ΄ΠΈΡΡΡΡΠ΅Π³ΠΎ ΡΠ΅ΠΊΡΠ΅ΡΠΈΡΡΠ΅ΠΌΡΠΉ Π±Π΅Π»ΠΎΠΊ. ΠΠΎΠ²ΡΡΠ΅Π½ΠΈΠ΅ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ PDGFA ΠΈ GPC3 Π²ΡΡΠ²Π»Π΅Π½ΠΎ Π² 17 ΠΈΠ· 19 ΠΎΠ±ΡΠ°Π·ΡΠΎΠ² ΠΠ ΠΈ Π² Π±ΠΎΠ»ΡΡΠΈΠ½ΡΡΠ²Π΅ ΡΠ»ΡΡΠ°Π΅Π² ΠΈΠ· Π±Π°Π· Π΄Π°Π½Π½ΡΡ
. Π‘ΠΎΠ²ΠΌΠ΅ΡΡΠ½ΠΎΠ΅ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ Π΄Π²ΡΡ
ΠΌΠ°ΡΠΊΠ΅ΡΠ½ΡΡ
Π³Π΅Π½ΠΎΠ² PDGFA ΠΈ GPC3 ΠΏΠΎΠ·Π²ΠΎΠ»ΡΠ΅Ρ Π΄ΠΈΡΡΠ΅ΡΠ΅Π½ΡΠΈ-ΡΠΎΠ²Π°ΡΡ ΡΠΊΠ°Π½Ρ ΠΠ ΠΎΡ Π½Π΅ΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΠΎΠΉ ΡΠΊΠ°Π½ΠΈ ΠΏΠ΅ΡΠ΅Π½ΠΈ Π»ΡΡΡΠ΅, ΡΠ΅ΠΌ PDGFA ΠΈΠ»ΠΈ GPC3 ΠΏΠΎ ΠΎΡΠ΄Π΅Π»ΡΠ½ΠΎΡΡΠΈ. ΠΠΈΠΏΠ΅ΡΡΠΊΡΠΏΡΠ΅ΡΡΠΈΡ PDGFA Π°ΡΡΠΎ-ΡΠΈΠΈΡΠΎΠ²Π°Π½Π° Ρ Π»ΡΡΡΠΈΠΌ ΠΏΡΠΎΠ³Π½ΠΎΠ·ΠΎΠΌ Π΄Π»Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΡΠ°Π½Π½ΠΈΠΌΠΈ ΡΡΠ°Π΄ΠΈΡΠΌΠΈ ΠΠ ΠΈ Π½ΠΈΠ·ΠΊΠΎΠΉ ΠΈΠ½Π²Π°Π·ΠΈΠ΅ΠΉ ΠΎΠΏΡΡ
ΠΎΠ»ΠΈ Π² ΡΠΎΡΡΠ΄Ρ. ΠΡΠ²ΠΎΠ΄Ρ. PDGFA β ΠΏΠ΅ΡΡΠΏΠ΅ΠΊΡΠΈΠ²Π½ΡΠΉ ΡΠ΅ΠΊΡΠ΅ΡΠΈΡΡΠ΅ΠΌΡΠΉ Π±ΠΈΠΎΠΌΠ°ΡΠΊΠ΅Ρ ΠΠ, ΠΊΠΎΡΠΎΡΡΠΉ ΠΌΠΎΠΆΠ΅Ρ Π±ΡΡΡ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ Π²ΠΌΠ΅ΡΡΠ΅ Ρ GPC3 Π΄Π»Ρ ΠΏΠΎΠ²ΡΡΠ΅Π½ΠΈΡ Π΅Π³ΠΎ ΡΡΠ²ΡΡΠ²ΠΈ-ΡΠ΅Π»ΡΠ½ΠΎΡΡΠΈ
ΠΠ΅Π½ΠΈΠ½Π³ΠΎΠΊΠΎΠΊΠΊΠΎΠ²ΡΠ΅ Π²Π°ΠΊΡΠΈΠ½Ρ: ΠΎΡ ΠΊΠ°ΠΏΡΡΠ»ΡΠ½ΡΡ ΠΏΠΎΠ»ΠΈΡΠ°Ρ Π°ΡΠΈΠ΄ΠΎΠ² Π΄ΠΎ ΠΏΡΠΎΡΠ΅Π°Π·
Microbial capsular polysaccharides for many years provided a highly practical public health vaccines for preventing meningococcal, pneumococcal and Haemophilus influenza infection, and typhoid fever. Their application in the form of conjugates with protein carriers eliminate the gap in protection against these infections in children under one year. Extremely promising turned out offered us a new generation of vaccines, which have synthetic peptides conjugated to a meningococcal polysaccharide. Thus, new approaches to the solution of the problem of meningococcal disease vaccination serogroup B were open. In recent years, Russian researchers first suggested to use IgA1 protease (one of the major virulence factors of microbes and almost identical for mentioned below infections) for prevention of such diseases as meningococcal of all serogroups, pneumococcus and hemophilia infections. Patented processes for producing of the vaccine define domestic priority of its production and use.ΠΠΈΠΊΡΠΎΠ±Π½ΡΠ΅ ΠΊΠ°ΠΏΡΡΠ»ΡΠ½ΡΠ΅ ΠΏΠΎΠ»ΠΈΡΠ°Ρ
Π°ΡΠΈΠ΄Ρ Π½Π° ΠΏΡΠΎΡΡΠΆΠ΅Π½ΠΈΠΈ ΠΌΠ½ΠΎΠ³ΠΈΡ
Π»Π΅Ρ ΠΎΠ±Π΅ΡΠΏΠ΅ΡΠΈΠ²Π°Π»ΠΈ ΠΏΡΠ°ΠΊΡΠΈΡΠ΅ΡΠΊΠΎΠ΅ Π·Π΄ΡΠ°Π²ΠΎΠΎΡ
ΡΠ°Π½Π΅Π½ΠΈΠ΅ Π²ΡΡΠΎΠΊΠΎΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΡΠΌΠΈ Π²Π°ΠΊΡΠΈΠ½Π°ΠΌΠΈ Π΄Π»Ρ ΠΏΡΠΎΡΠΈΠ»Π°ΠΊΡΠΈΠΊΠΈ ΠΌΠ΅Π½ΠΈΠ½Π³ΠΎΠΊΠΎΠΊΠΊΠΎΠ²ΡΡ
, ΠΏΠ½Π΅Π²ΠΌΠΎΠΊΠΎΠΊΠΊΠΎΠ²ΡΡ
, Π³Π΅ΠΌΠΎΡΠΈΠ»ΡΠ½ΡΡ
ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΉ ΠΈ Π±ΡΡΡΠ½ΠΎΠ³ΠΎ ΡΠΈΡΠ°. Π ΠΈΡ
ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ Π² Π²ΠΈΠ΄Π΅ ΠΊΠΎΠ½ΡΡΠ³Π°ΡΠΎΠ² Ρ Π±Π΅Π»ΠΊΠΎΠ²ΡΠΌΠΈ Π½ΠΎΡΠΈΡΠ΅Π»ΡΠΌΠΈ Π»ΠΈΠΊΠ²ΠΈΠ΄ΠΈΡΠΎΠ²Π°Π»ΠΎ ΠΏΡΠΎΠ±Π΅Π» ΠΏΡΠΈ Π·Π°ΡΠΈΡΠ΅ ΠΎΡ ΡΡΠΈΡ
ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΉ Π΄Π΅ΡΠ΅ΠΉ Π² Π²ΠΎΠ·ΡΠ°ΡΡΠ΅ Π΄ΠΎ ΠΎΠ΄Π½ΠΎΠ³ΠΎ Π³ΠΎΠ΄Π°. ΠΠ΅ΠΎΠ±ΡΡΠ°ΠΉΠ½ΠΎ ΠΏΠ΅ΡΡΠΏΠ΅ΠΊΡΠΈΠ²Π½ΡΠΌ ΠΎΠΊΠ°Π·Π°Π»ΠΎΡΡ ΠΏΡΠ΅Π΄Π»ΠΎΠΆΠ΅Π½Π½ΠΎΠ΅ Π½Π°ΠΌΠΈ Π½ΠΎΠ²ΠΎΠ΅ ΠΏΠΎΠΊΠΎΠ»Π΅Π½ΠΈΠ΅ Π²Π°ΠΊΡΠΈΠ½, Π³Π΄Π΅ ΡΠΆΠ΅ ΡΠΈΠ½ΡΠ΅ΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΏΠ΅ΠΏΡΠΈΠ΄Ρ ΠΊΠΎΠ½ΡΡΠ³ΠΈΡΠΎΠ²Π°Π»ΠΈΡΡ Ρ ΠΏΠΎΠ»ΠΈΡΠ°Ρ
Π°ΡΠΈΠ΄Π°ΠΌΠΈ ΠΌΠ΅Π½ΠΈΠ½Π³ΠΎΠΊΠΎΠΊΠΊΠΎΠ². Π’Π°ΠΊΠΈΠΌ ΠΎΠ±ΡΠ°Π·ΠΎΠΌ, Π±ΡΠ»ΠΈ ΠΎΡΠΊΡΡΡΡ ΠΏΠΎΠ΄Ρ
ΠΎΠ΄Ρ ΠΊ ΡΠ΅ΡΠ΅Π½ΠΈΡ ΠΏΡΠΎΠ±Π»Π΅ΠΌΡ Π²Π°ΠΊΡΠΈΠ½ΠΎΠΏΡΠΎΡΠΈΠ»Π°ΠΊΡΠΈΠΊΠΈ ΠΌΠ΅Π½ΠΈΠ½Π³ΠΎΠΊΠΎΠΊΠΊΠΎΠ²ΠΎΠΉ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ ΡΠ΅ΡΠΎΠ³ΡΡΠΏΠΏΡ Π. Π ΠΏΠΎΡΠ»Π΅Π΄Π½ΠΈΠ΅ Π³ΠΎΠ΄Ρ ΠΎΡΠ΅ΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°ΡΠ΅Π»ΠΈ Π²ΠΏΠ΅ΡΠ²ΡΠ΅ ΠΏΡΠ΅Π΄Π»ΠΎΠΆΠΈΠ»ΠΈ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°ΡΡ Π΄Π»Ρ ΠΏΡΠΎΡΠΈΠ»Π°ΠΊΡΠΈΠΊΠΈ ΠΌΠ΅Π½ΠΈΠ½Π³ΠΎΠΊΠΎΠΊΠΊΠΎΠ²ΡΡ
ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΉ Π²ΡΠ΅Ρ
ΡΠ΅ΡΠΎΠ³ΡΡΠΏΠΏ, Π° ΡΠ°ΠΊΠΆΠ΅ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΉ, ΠΎΠ±ΡΡΠ»ΠΎΠ²Π»Π΅Π½Π½ΡΡ
ΠΏΠ½Π΅Π²ΠΌΠΎΠΊΠΎΠΊΠΊΠ°ΠΌΠΈ ΠΈ Π³Π΅ΠΌΠΎΡΠΈΠ»Π°ΠΌΠΈ, ΠΎΠ΄ΠΈΠ½ ΠΈΠ· Π³Π»Π°Π²Π½ΡΡ
ΡΠ°ΠΊΡΠΎΡΠΎΠ² Π²ΠΈΡΡΠ»Π΅Π½ΡΠ½ΠΎΡΡΠΈ ΡΡΠΈΡ
ΠΌΠΈΠΊΡΠΎΠ±ΠΎΠ² β IgA1 ΠΏΡΠΎΡΠ΅Π°Π·Ρ, ΠΏΡΠ°ΠΊΡΠΈΡΠ΅ΡΠΊΠΈ ΠΈΠ΄Π΅Π½ΡΠΈΡΠ½ΡΡ Π΄Π»Ρ Π²ΡΠ΅ΠΉ ΡΠΊΠ°Π·Π°Π½Π½ΠΎΠΉ Π³ΡΡΠΏΠΏΡ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΉ. ΠΠ°ΠΏΠ°ΡΠ΅Π½ΡΠΎΠ²Π°Π½Π½ΡΠ΅ ΡΠΏΠΎΡΠΎΠ±Ρ ΠΏΠΎΠ»ΡΡΠ΅Π½ΠΈΡ ΡΡΠΎΠΉ Π²Π°ΠΊΡΠΈΠ½Ρ ΠΎΠΏΡΠ΅Π΄Π΅Π»ΡΡΡ ΠΎΡΠ΅ΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΠΉ ΠΏΡΠΈΠΎΡΠΈΡΠ΅Ρ Π΅Π΅ ΠΏΡΠΎΠΈΠ·Π²ΠΎΠ΄ΡΡΠ²Π° ΠΈ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ
NGS-based identification of druggable alterations and signaling pathways β hepatocellular carcinoma case report
Aim. To identify potential cancer driving or clinically relevant molecular events for a patient with hepatocellular carcinoma. Methods. In order to achieve this goal, we performed RNA-seq and exome sequencing for the tumor tissue and its matched control. We annotated the alterations found using several publicly available databases and bioinformatics tools. Results. We identified several differentially expressed genes linked to the classical sorafenib treatment as well as additional pathways potentially druggable by therapies studied in clinical trials (Erlotinib, Lapatinib and Temsirolimus). Several germline mutations, found in XRCC1, TP53 and DPYD, according to the data from other clinical trials, could be related to the increased sensitivity to platinum therapies and reduced sensitivity to 5-Fluorouracil. We also identified several potentially driving mutations that could not be currently linked to therapies, like deletion in CIRBP, SNVs in BTG1, ERBB3, TCF7L2 et al. Conclusions. The presented study shows the potential usefulness of the integrated approach to the NGS data analysis, including the analysis of germline mutations and transcriptome in addition to the cancer panel or the exome sequencing data.ΠΠ΅ΡΠ°. ΠΠ΄Π΅Π½ΡΠΈΡΡΠΊΡΠ²Π°ΡΠΈ ΠΏΠΎΡΠ΅Π½ΡΡΠΉΠ½ΠΎ ΠΎΠ½ΠΊΠΎΠ΄ΡΠ°ΠΉΠ²Π΅ΡΠ½Ρ Π°Π±ΠΎ ΠΊΠ»ΡΠ½ΡΡΠ½ΠΎ Π·Π½Π°ΡΡΡΡ ΠΌΠΎΠ»Π΅ΠΊΡΠ»ΡΡΠ½Ρ ΠΏΠΎΠ΄ΡΡ Ρ ΠΏΠ°ΡΡΡΠ½ΡΠ° Π· Π³Π΅ΠΏΠ°ΡΠΎΠΊΠ»ΡΡΠΈΠ½Π½ΠΎΡ ΠΊΠ°ΡΡΠΈΠ½ΠΎΠΌΠΎΡ. ΠΠ΅ΡΠΎΠ΄ΠΈ. Π ΠΠ- ΡΠ° Π΅ΠΊΠ·ΠΎΠΌΠ½Π΅ ΡΠ΅ΠΊΠ²Π΅Π½ΡΠ²Π°Π½Π½Ρ ΠΏΡΡ
Π»ΠΈΠ½Π½ΠΎΡ ΡΠΊΠ°Π½ΠΈΠ½ΠΈ ΡΠ° Π²ΡΠ΄ΠΏΠΎΠ²ΡΠ΄Π½ΠΎΠ³ΠΎ ΠΊΠΎΠ½ΡΡΠΎΠ»Ρ. ΠΠ½ΠΎΡΡΠ²Π°Π½Π½Ρ Π·Π½Π°ΠΉΠ΄Π΅Π½ΠΈΡ
Π·ΠΌΡΠ½, Π²ΠΈΠΊΠΎΡΠΈΡΡΠΎΠ²ΡΡΡΠΈ Π΄Π΅ΠΊΡΠ»ΡΠΊΠ° Π·Π°Π³Π°Π»ΡΠ½ΠΎΠ΄ΠΎΡΡΡΠΏΠ½ΠΈΡ
Π±Π°Π· Π΄Π°Π½ΠΈΡ
ΡΠ° Π±ΡΠΎΡΠ½ΡΠΎΡΠΌΠ°ΡΠΈΡΠ½ΠΈΡ
ΠΏΡΠΎΠ³ΡΠ°ΠΌ. ΠΠΈ ΡΠ°ΠΊΠΎΠΆ ΠΏΠΎΡΡΠ²Π½ΡΠ»ΠΈ ΡΡΠ°Π½ΡΠΊΡΠΈΠΏΡΡΠΉΠ½ΠΈΠΉ ΠΏΡΠΎΡΡΠ»Ρ Π΄ΠΎΡΠ»ΡΠ΄ΠΆΡΠ²Π°Π½ΠΎΡ ΠΏΡΡ
Π»ΠΈΠ½ΠΈ Π· ΡΡΠ°Π½ΡΠΊΡΠΈΠΏΡΠΎΠΌΠ°ΠΌΠΈ ΠΊΠ»ΡΡΠΈΠ½Π½ΠΈΡ
Π»ΡΠ½ΡΠΉ Π· Π±Π°Π·ΠΈ Π΄Π°Π½ΠΈΡ
Genomics of Drug Sensitivity in Cancer. Π Π΅Π·ΡΠ»ΡΡΠ°ΡΠΈ. ΠΠ΄Π΅Π½ΡΠΈΡΡΠΊΠΎΠ²Π°Π½ΠΎ ΠΊΡΠ»ΡΠΊΠ° Π³Π΅Π½ΡΠ², ΡΠΎ Π΄ΠΈΡΡΠ΅ΡΠ΅Π½ΡΡΠΉΠ½ΠΎ Π΅ΠΊΡΠΏΡΠ΅ΡΡΡΡΡΡΡ, Ρ ΠΏΠΎΠ²βΡΠ·Π°Π½Ρ ΡΠΊ Π· ΠΊΠ»Π°ΡΠΈΡΠ½ΠΎΡ ΡΠ΅ΡΠ°ΠΏΡΡΡ ΡΠΎΡΠ°ΡΠ΅Π½ΡΠ±ΠΎΠΌ, ΡΠ°ΠΊ Ρ Π· Π΄ΠΎΠ΄Π°ΡΠΊΠΎΠ²ΠΈΠΌΠΈ ΡΠΈΠ³Π½Π°Π»ΡΠ½ΠΈΠΌΠΈ ΡΠ»ΡΡ
Π°ΠΌΠΈ, ΡΠΎ ΠΏΠΎΡΠ΅Π½ΡΡΠΉΠ½ΠΎ Π²ΡΠ°Π·Π»ΠΈΠ²Ρ Π΄ΠΎ ΡΠ΅ΡΠ°ΠΏΡΡ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ°ΠΌΠΈ, ΡΠΊΡ Π΄ΠΎΡΠ»ΡΠ΄ΠΆΡΠ²Π°Π»ΠΈΡΡ Ρ ΠΊΠ»ΡΠ½ΡΡΠ΅ΡΠΊΠΈΡ
Π²ΠΈΠΏΡΠΎΠ±ΡΠ²Π°Π½Π½ΡΡ
(Π΅ΡΠ»ΠΎΡΡΠ½ΡΠ±, Π»Π°ΠΏΠ°ΡΡΠ½ΡΠ± ΡΠ° ΡΠ΅ΠΌΡΡΡΠΎΠ»ΡΠΌΡΡ). ΠΠ΅ΠΊΡΠ»ΡΠΊΠ° Π³Π΅ΡΠΌΡΠ½Π°ΡΠΈΠ²Π½ΠΈΡ
ΠΌΡΡΠ°ΡΡΠΉ, Π·Π½Π°ΠΉΠ΄Π΅Π½ΠΈΡ
Π² XRCC1, TP53 ΡΠ° DPYD, Π·Π³ΡΠ΄Π½ΠΎ Π· Π΄Π°Π½ΠΈΠΌΠΈ ΡΠ½ΡΠΈΡ
ΠΊΠ»ΡΠ½ΡΡΠ½ΠΈΡ
Π²ΠΈΠΏΡΠΎΠ±ΡΠ²Π°Π½Ρ, ΠΌΠΎΠΆΡΡΡ Π±ΡΡΠΈ ΠΏΠΎΠ²βΡΠ·Π°Π½Ρ Π· ΠΏΡΠ΄Π²ΠΈΡΠ΅Π½ΠΎΡ ΡΡΡΠ»ΠΈΠ²ΡΡΡΡ Π΄ΠΎ ΠΏΠ»Π°ΡΠΈΠ½ΠΎΠ²ΠΈΡ
ΡΠ΅ΡΠ°ΠΏΡΠΉ ΡΠ° Π·ΠΌΠ΅Π½ΡΠ΅Π½ΠΎΡ ΡΡΡΠ»ΠΈΠ²ΡΡΡΡ Π΄ΠΎ 5-ΡΡΠΎΡΡΡΠ°ΡΠΈΠ»Ρ. ΠΠΈ ΡΠ°ΠΊΠΎΠΆ ΡΠ΄Π΅Π½ΡΠΈΡΡΠΊΡΠ²Π°Π»ΠΈ Π΄Π΅ΠΊΡΠ»ΡΠΊΠ° ΠΏΠΎΡΠ΅Π½ΡΡΠΉΠ½ΠΎ Π΄ΡΠ°ΠΉΠ²Π΅ΡΠ½ΠΈΡ
ΠΌΡΡΠ°ΡΡΠΉ, ΡΠΊΡ Π½Π° ΡΠ΅ΠΉ ΡΠ°Ρ Π½Π΅ ΠΌΠΎΠΆΡΡΡ Π±ΡΡΠΈ ΠΏΠΎΠ²βΡΠ·Π°Π½Ρ Π· ΡΠ΅ΡΠ°ΠΏΡΡΠΌΠΈ, Π½Π°ΠΏΡΠΈΠΊΠ»Π°Π΄ Π΄Π΅Π»Π΅ΡΡΡ Ρ CIRBP, Π·Π°ΠΌΡΠ½ΠΈ Π² BTG1, ERBB3, TCF7L2 ΡΠΎΡΠΎ. ΠΠΈΡΠ½ΠΎΠ²ΠΊΠΈ. ΠΠ°ΠΏΡΠΎΠΏΠΎΠ½ΠΎΠ²Π°Π½Π΅ Π΄ΠΎΡΠ»ΡΠ΄ΠΆΠ΅Π½Π½Ρ Π΄Π΅ΠΌΠΎΠ½ΡΡΡΡΡ ΠΏΠΎΡΠ΅Π½ΡΡΠΉΠ½Ρ ΠΊΠΎΡΠΈΡΠ½ΡΡΡΡ ΡΠ½ΡΠ΅Π³ΡΠΎΠ²Π°Π½ΠΎΠ³ΠΎ ΠΏΡΠ΄Ρ
ΠΎΠ΄Ρ Π΄ΠΎ NGS Π°Π½Π°Π»ΡΠ·Ρ Π΄Π°Π½ΠΈΡ
, Π² ΡΠΎΠΌΡ ΡΠΈΡΠ»Ρ Π°Π½Π°Π»ΡΠ·Ρ Π³Π΅ΡΠΌΡΠ½Π°ΡΠΈΠ²Π½ΠΈΡ
ΠΌΡΡΠ°ΡΡΠΉ ΡΠ° ΡΡΠ°Π½ΡΠΊΡΠΈΠΏΡΠΎΠΌΡ Ρ Π΄ΠΎΠ΄Π°ΡΠΎΠΊ Π΄ΠΎ Π²ΠΈΠΊΠΎΡΠΈΡΡΠ°Π½Π½Ρ ΠΎΠ½ΠΊΠΎΠ»ΠΎΠ³ΡΡΠ½ΠΈΡ
Π³Π΅Π½Π½ΠΈΡ
ΠΏΠ°Π½Π΅Π»Π΅ΠΉ Π°Π±ΠΎ Π΄Π°Π½ΠΈΡ
ΡΠ΅ΠΊΠ²Π΅Π½ΡΠ²Π°Π½Π½Ρ Π΅ΠΊΠ·ΠΎΠΌΡ.Π¦Π΅Π»Ρ. ΠΡΡΠ²Π»Π΅Π½ΠΈΠΈ ΠΊΠ»ΡΡΠ΅Π²ΡΡ
ΠΈΠ»ΠΈ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈ Π·Π½Π°ΡΠΈΠΌΡΡ
ΠΌΠΎΠ»Π΅ΠΊΡΠ»ΡΡΠ½ΡΡ
ΡΠΎΠ±ΡΡΠΈΠΉ Π΄Π»Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ° Ρ Π³Π΅ΠΏΠ°ΡΠΎΡΠ΅Π»Π»ΡΠ»ΡΡΠ½ΠΎΠΉ ΠΊΠ°ΡΡΠΈΠ½ΠΎΠΌΠΎΠΉ. ΠΠ΅ΡΠΎΠ΄Ρ. Π ΠΠ- ΠΈ ΡΠΊΠ·ΠΎΠΌΠ½ΠΎΠ΅ ΡΠ΅ΠΊΠ²Π΅Π½ΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΠΎΠΉ ΠΈ Π½ΠΎΡΠΌΠ°Π»ΡΠ½ΠΎΠΉ ΡΠΊΠ°Π½ΠΈ. ΠΡ ΠΏΡΠΎΠ°Π½Π½ΠΎΡΠΈΡΠΎΠ²Π°Π»ΠΈ Π½Π°ΠΉΠ΄Π΅Π½Π½ΡΠ΅ Π³Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ Π½Π°ΡΡΡΠ΅Π½ΠΈΡ, ΠΈΡΠΏΠΎΠ»ΡΠ·ΡΡ Π½Π΅ΡΠΊΠΎΠ»ΡΠΊΠΎ ΠΎΠ±ΡΠ΅Π΄ΠΎΡΡΡΠΏΠ½ΡΡ
Π±Π°Π· Π΄Π°Π½Π½ΡΡ
ΠΈ Π±ΠΈΠΎΠΈΠ½ΡΠΎΡΠΌΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΈΠ½ΡΡΡΡΠΌΠ΅Π½ΡΠΎΠ². Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. ΠΡ ΠΎΠΏΡΠ΅Π΄Π΅Π»ΠΈΠ»ΠΈ Π½Π΅ΡΠΊΠΎΠ»ΡΠΊΠΎ Π΄ΠΈΡΡΠ΅ΡΠ΅Π½ΡΠΈΠ°Π»ΡΠ½ΠΎ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
Π³Π΅Π½ΠΎΠ², ΡΠ²ΡΠ·Π°Π½Π½ΡΡ
Ρ ΠΊΠ»Π°ΡΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΡ
Π΅ΠΌΠΎΠΉ Π»Π΅ΡΠ΅Π½ΠΈΡ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠΌ ΡΠΎΡΠ°ΡΠ΅Π½ΠΈΠ±, Π° ΡΠ°ΠΊΠΆΠ΅ Π΄ΠΎΠΏΠΎΠ»Π½ΠΈΡΠ΅Π»ΡΠ½ΡΠ΅ ΠΏΡΡΠΈ ΠΏΠΎΡΠ΅Π½ΡΠΈΠ°Π»ΡΠ½ΠΎ ΠΏΠΎΠ΄Π΄Π°ΡΡΠΈΠ΅ΡΡ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ°ΠΌΠΈ, Π²ΠΊΠ»ΡΡΠ΅Π½Π½ΡΠΌΠΈ Π² ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΈΡΠΏΡΡΠ°Π½ΠΈΡ (ΠΡΠ»ΠΎΡΠΈΠ½ΠΈΠ±, ΠΠ°ΠΏΠ°ΡΠΈΠ½ΠΈΠ± ΠΈ Π’Π΅ΠΌΡΠΈΡΠΎΠ»ΠΈΠΌΡΡ). ΠΠ΅ΡΠΊΠΎΠ»ΡΠΊΠΎ Π³Π΅ΡΠΌΠΈΠ½Π°ΡΠΈΠ²Π½ΡΡ
ΠΌΡΡΠ°ΡΠΈΠΉ, Π½Π°ΠΉΠ΄Π΅Π½Π½ΡΡ
Π² XRCC1, TP53 ΠΈ DPYD, ΠΏΠΎ Π΄Π°Π½Π½ΡΠΌ ΠΈΠ· Π΄ΡΡΠ³ΠΈΡ
ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΈΡΠΏΡΡΠ°Π½ΠΈΠΉ, ΠΌΠΎΠ³ΡΡ Π±ΡΡΡ ΡΠ²ΡΠ·Π°Π½Ρ Ρ ΠΏΠΎΠ²ΡΡΠ΅Π½Π½ΠΎΠΉ ΡΡΠ²ΡΡΠ²ΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΡΡ ΠΊ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ°ΠΌ ΠΏΠ»Π°ΡΠΈΠ½Ρ ΠΈ ΠΏΠΎΠ½ΠΈΠΆΠ΅Π½Π½ΠΎΠΉ ΡΡΠ²ΡΡΠ²ΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΡΡ ΠΊ 5-ΡΡΠΎΡΡΡΠ°ΡΠΈΠ»Ρ. ΠΡ ΡΠ°ΠΊΠΆΠ΅ ΠΎΠΏΡΠ΅Π΄Π΅Π»ΠΈΠ»ΠΈ Π½Π΅ΡΠΊΠΎΠ»ΡΠΊΠΎ ΠΏΠΎΡΠ΅Π½ΡΠΈΠ°Π»ΡΠ½ΠΎ Π΄ΡΠ°ΠΉΠ²Π΅ΡΠ½ΡΡ
ΠΌΡΡΠ°ΡΠΈΠΉ Π² Π³Π΅Π½Π°Ρ
CIRBP, Π·Π°ΠΌΠ΅Π½Ρ Π² BTG1, ErbB3, TCF7L2 ΠΈ Π΄Ρ., ΠΊΠΎΡΠΎΡΡΠ΅ Π² Π½Π°ΡΡΠΎΡΡΠ΅Π΅ Π²ΡΠ΅ΠΌΡ Π½Π΅ ΡΠ²ΡΠ·Π°Π½Ρ Ρ ΡΠ΅ΡΠ°ΒΠΏΠΈΠ΅ΠΉ. ΠΡΠ²ΠΎΠ΄Ρ. ΠΠ°Π½Π½ΠΎΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ ΠΏΠΎΠΊΠ°Π·ΡΠ²Π°Π΅Ρ ΠΏΠΎΡΠ΅Π½ΡΠΈΠ°Π»ΡΠ½ΡΡ Π·Π½Π°ΡΠΈΠΌΠΎΡΡΡ ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠ½ΠΎΠ³ΠΎ ΠΏΠΎΠ΄Ρ
ΠΎΠ΄Π° ΠΊ Π°Π½Π°Π»ΠΈΠ·Ρ Π΄Π°Π½Π½ΡΡ
NGS, Π² ΡΠΎΠΌ ΡΠΈΡΠ»Π΅ Π°Π½Π°Π»ΠΈΠ·Π° Π³Π΅ΡΠΌΠΈΠ½Π°ΡΠΈΠ²Π½ΡΡ
ΠΌΡΡΠ°ΡΠΈΠΉ ΠΈ ΡΡΠ°Π½ΡΠΊΡΠΈΠΏΡΠΎΠΌΠ° Π² Π΄ΠΎΠΏΠΎΠ»Π½Π΅Π½ΠΈΠ΅ ΠΊ Π΄Π°Π½Π½ΡΠΌ ΠΈΠ· Π³Π΅Π½Π½ΡΡ
ΠΏΠ°Π½Π΅Π»Π΅ΠΉ ΠΈΠ»ΠΈ ΡΠ΅ΠΊΠ²Π΅Π½ΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΡΠΊΠ·ΠΎΠΌΠ°
2D Seismic Interpretation and Characterization of the Upper Qishn Clastics in Sharyoof Oil Field, Masila Basin, Yemen
The Sharyoof oil field is located off shore in Block 53 in the northeastern part of the Syaun-Masilah Basin, in the province of Hadramaut, 550 km from the city of Sana'a, the capital of Yemen. Fifteen 2D seismic lines along with six wells data are used to construct subsurface geological profile, and to identify major structural features in the study area. Synthetic seismograms have been constructed using sonic and density log for all available wells to tie horizons to seismic data and to generate time and depth subsurface maps. This research has been carried out using integrated 2D seismic and petrophysical studies in Sharyoof oilfield. Using the analysis and interpretation of seismic data, the main structural faults were identified, maps of isochrones, structural maps of depth and thickness were constructed, which subsequently will allow us to correctly determine the deep geological structures in Upper Qishn Clastics member and evaluate the oil horizons of the Sharyoof oilfield. Β© Published under licence by IOP Publishing Ltd
Current approaches to the verification of bacterial vaginosis diagnosis and treatment tactics
Current approaches to the verification of bacterial vaginosis diagnosis and treatment tactics
Pestrikova T.Yu., Yurasova E.A., Kotelnikova A.V., KnyazevΠ° T.P.
Far Eastern State Medical University
The prevalence of bacterial vaginosis varies widely. Its incidence amounts to 35% of all gynecological pathologies; 10β30% β in pregnant women; 20β60% β in patients treated for sexually transmitted infections.
The article presents the current data on epidemiology, etiology, diagnosis, and treatment of this pathology. It is emphasized that the use of the real-time polymerase chain reaction method is reasonable for the diagnosis of bacterial vaginosis.
During the treatment, special attention is paid to the use of a combination of metronidazole + miconazole. This drug is effective for the treatment of bacterial vaginosis, vulvovaginal candidiasis, mixed vaginitis infections.
The combined drug (metronidazole + miconazole) is effective against aerobic and anaerobic microbial agents, including Gardnerella vaginalis, and against Candida albicans, Trichomonas vaginalis, Entamoeba histolytica, etc., which makes it possible to use it for the treatment of both bacterial vaginosis and its combination with candidal vulvovaginitis.
Key words: bacterial vaginosis, real-time polymerase chain reaction, candidiasis vulvovaginitis, combined drug (metronidazole + miconazole).
For citation: Pestrikova T.Yu., Yurasova E.A., Kotelnikova A.V., Knyazeva T.P. Current approaches to the verification of bacterial vaginosis diagnosis and treatment tactics // RMJ. 2018. β 2(I). P. 48β53.<br
Mineral chemistry and petrology of mantle peridotites from the qala en nahal-umm saqata ophiolite, gedarif state, sudan
The study area of this research some 70 km southwest of Gedarif city, Gedarif State, in eastern Sudan. With a geological position, it is located within two major lithological associations, representing two different crustal entities: Saharan Meta-craton (SMC) in the west and the Arabian Nubian Shield (ANS) to the east. The main objective of the study is a petrological investigation of the mantle peridotites within Qala En Nahal-Umm Saqata area. The relatively large-scale exposed masses of mantleβs peridotite, include mainly the Utash mass and the Umm Saqata mass in the south and the Qala en Nahal mass and the Fau mass in the north of the area. Petrographically, they are mostly serpentinite. They have low-contents of Al2 O3, CaO, TiO 2, MgO, Na2O and K2O, all consistent with depleted mantle materials, and similar to the metamorphic peridotites. The analyzed serpentine minerals are mainly pseudomorphic serpentines with subordinate antigorite, which may suggest that the parent minerals were first retrogressed to form lizardite and chrysotile. Subsequently, progressive metamorphism has recrystallized these minerals into antigorite. The chromites from the study area have high Cr# (Cr# varies from 0.51 to 0.87), most probably representing the primary phase which is similar to chromian spinels in mantle-derived peridotites. The presence of podiform chromites in the studied serpentinites is e typical of supra-subduction ophiolites, with Cr# similar to those of forearc ophiolites and boninite-derived chromites. Qala En Nahal-Umm Saqata mantle peridotites were formed in a forearc setting, during the subduction initiation that developed as a result of southeastward-dipping subduction zone. They possibly represent ensimatic, thrusted material, after the collision of the Nubian-Arabian Shield with the older sialic continental Saharan Metacra-ton during the late Proterozoic, Pan-African tectono-thermal event. Β© 2021, Ore and Metals Publishing house. All rights reserved
Serological Analysis of Immunogenic Properties of Recombinant Meningococcus IgA1 Protease-Based Proteins
Using the genome sequence of IgA1 protease of N. meningitidis of serogroup B, four recombinant proteins of different structure and molecular weight were constructed. These proteins were equal in inducing the formation of specific antibodies to IgA1 protease and had protective properties against meningococci. In the sera of immunized mice, anti-IgA1 protease antibodies were detected by whole-cell ELISA, which indicated the presence of IgA1 protease on the surface of these bacteria. We hypothesized that the protective properties of IgA1 protease-based antigens and IgA1 protease analogs could be realized not only via impairment of bacterium adhesion to the mucosa, but also via suppression of this pathogen in the organism. The presented findings seem promising for using these proteins as the basis for anti-meningococcus vaccine. Β© 2016, Springer Science+Business Media New York
Serological Analysis of Immunogenic Properties of Recombinant Meningococcus IgA1 Protease-Based Proteins
Using the genome sequence of IgA1 protease of N. meningitidis of serogroup B, four recombinant proteins of different structure and molecular weight were constructed. These proteins were equal in inducing the formation of specific antibodies to IgA1 protease and had protective properties against meningococci. In the sera of immunized mice, anti-IgA1 protease antibodies were detected by whole-cell ELISA, which indicated the presence of IgA1 protease on the surface of these bacteria. We hypothesized that the protective properties of IgA1 protease-based antigens and IgA1 protease analogs could be realized not only via impairment of bacterium adhesion to the mucosa, but also via suppression of this pathogen in the organism. The presented findings seem promising for using these proteins as the basis for anti-meningococcus vaccine. Β© 2016, Springer Science+Business Media New York
NGS-based identification of druggable alterations and signaling pathways – hepatocellular carcinoma case report
Aim. To identify potential cancer driving or clinically relevant molecular events for a patient with hepatocellular carcinoma. Methods. In order to achieve this goal, we performed RNA-seq and exome sequencing for the tumor tissue and its matched control. We annotated the alterations found using several publicly available databases and bioinformatics tools. Results. We identified several differentially expressed genes linked to the classical sorafenib treatment as well as additional pathways potentially druggable by therapies studied in clinical trials (Erlotinib, Lapatinib and Temsirolimus). Several germline mutations, found in XRCC1, TP53 and DPYD, according to the data from other clinical trials, could be related to the increased sensitivity to platinum therapies and reduced sensitivity to 5-Fluorouracil. We also identified several potentially driving mutations that could not be currently linked to therapies, like deletion in CIRBP, SNVs in BTG1, ERBB3, TCF7L2 et al. Conclusions. The presented study shows the potential usefulness of the integrated approach to the NGS data analysis, including the analysis of germline mutations and transcriptome in addition to the cancer panel or the exome sequencing data.ΠΠ΅ΡΠ°. ΠΠ΄Π΅Π½ΡΠΈΡΡΠΊΡΠ²Π°ΡΠΈ ΠΏΠΎΡΠ΅Π½ΡΡΠΉΠ½ΠΎ ΠΎΠ½ΠΊΠΎΠ΄ΡΠ°ΠΉΠ²Π΅ΡΠ½Ρ Π°Π±ΠΎ ΠΊΠ»ΡΠ½ΡΡΠ½ΠΎ Π·Π½Π°ΡΡΡΡ ΠΌΠΎΠ»Π΅ΠΊΡΠ»ΡΡΠ½Ρ ΠΏΠΎΠ΄ΡΡ Ρ ΠΏΠ°ΡΡΡΠ½ΡΠ° Π· Π³Π΅ΠΏΠ°ΡΠΎΠΊΠ»ΡΡΠΈΠ½Π½ΠΎΡ ΠΊΠ°ΡΡΠΈΠ½ΠΎΠΌΠΎΡ. ΠΠ΅ΡΠΎΠ΄ΠΈ. Π ΠΠ- ΡΠ° Π΅ΠΊΠ·ΠΎΠΌΠ½Π΅ ΡΠ΅ΠΊΠ²Π΅Π½ΡΠ²Π°Π½Π½Ρ ΠΏΡΡ
Π»ΠΈΠ½Π½ΠΎΡ ΡΠΊΠ°Π½ΠΈΠ½ΠΈ ΡΠ° Π²ΡΠ΄ΠΏΠΎΠ²ΡΠ΄Π½ΠΎΠ³ΠΎ ΠΊΠΎΠ½ΡΡΠΎΠ»Ρ. ΠΠ½ΠΎΡΡΠ²Π°Π½Π½Ρ Π·Π½Π°ΠΉΠ΄Π΅Π½ΠΈΡ
Π·ΠΌΡΠ½, Π²ΠΈΠΊΠΎΡΠΈΡΡΠΎΠ²ΡΡΡΠΈ Π΄Π΅ΠΊΡΠ»ΡΠΊΠ° Π·Π°Π³Π°Π»ΡΠ½ΠΎΠ΄ΠΎΡΡΡΠΏΠ½ΠΈΡ
Π±Π°Π· Π΄Π°Π½ΠΈΡ
ΡΠ° Π±ΡΠΎΡΠ½ΡΠΎΡΠΌΠ°ΡΠΈΡΠ½ΠΈΡ
ΠΏΡΠΎΠ³ΡΠ°ΠΌ. ΠΠΈ ΡΠ°ΠΊΠΎΠΆ ΠΏΠΎΡΡΠ²Π½ΡΠ»ΠΈ ΡΡΠ°Π½ΡΠΊΡΠΈΠΏΡΡΠΉΠ½ΠΈΠΉ ΠΏΡΠΎΡΡΠ»Ρ Π΄ΠΎΡΠ»ΡΠ΄ΠΆΡΠ²Π°Π½ΠΎΡ ΠΏΡΡ
Π»ΠΈΠ½ΠΈ Π· ΡΡΠ°Π½ΡΠΊΡΠΈΠΏΡΠΎΠΌΠ°ΠΌΠΈ ΠΊΠ»ΡΡΠΈΠ½Π½ΠΈΡ
Π»ΡΠ½ΡΠΉ Π· Π±Π°Π·ΠΈ Π΄Π°Π½ΠΈΡ
Genomics of Drug Sensitivity in Cancer. Π Π΅Π·ΡΠ»ΡΡΠ°ΡΠΈ. ΠΠ΄Π΅Π½ΡΠΈΡΡΠΊΠΎΠ²Π°Π½ΠΎ ΠΊΡΠ»ΡΠΊΠ° Π³Π΅Π½ΡΠ², ΡΠΎ Π΄ΠΈΡΡΠ΅ΡΠ΅Π½ΡΡΠΉΠ½ΠΎ Π΅ΠΊΡΠΏΡΠ΅ΡΡΡΡΡΡΡ, Ρ ΠΏΠΎΠ²βΡΠ·Π°Π½Ρ ΡΠΊ Π· ΠΊΠ»Π°ΡΠΈΡΠ½ΠΎΡ ΡΠ΅ΡΠ°ΠΏΡΡΡ ΡΠΎΡΠ°ΡΠ΅Π½ΡΠ±ΠΎΠΌ, ΡΠ°ΠΊ Ρ Π· Π΄ΠΎΠ΄Π°ΡΠΊΠΎΠ²ΠΈΠΌΠΈ ΡΠΈΠ³Π½Π°Π»ΡΠ½ΠΈΠΌΠΈ ΡΠ»ΡΡ
Π°ΠΌΠΈ, ΡΠΎ ΠΏΠΎΡΠ΅Π½ΡΡΠΉΠ½ΠΎ Π²ΡΠ°Π·Π»ΠΈΠ²Ρ Π΄ΠΎ ΡΠ΅ΡΠ°ΠΏΡΡ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ°ΠΌΠΈ, ΡΠΊΡ Π΄ΠΎΡΠ»ΡΠ΄ΠΆΡΠ²Π°Π»ΠΈΡΡ Ρ ΠΊΠ»ΡΠ½ΡΡΠ΅ΡΠΊΠΈΡ
Π²ΠΈΠΏΡΠΎΠ±ΡΠ²Π°Π½Π½ΡΡ
(Π΅ΡΠ»ΠΎΡΡΠ½ΡΠ±, Π»Π°ΠΏΠ°ΡΡΠ½ΡΠ± ΡΠ° ΡΠ΅ΠΌΡΡΡΠΎΠ»ΡΠΌΡΡ). ΠΠ΅ΠΊΡΠ»ΡΠΊΠ° Π³Π΅ΡΠΌΡΠ½Π°ΡΠΈΠ²Π½ΠΈΡ
ΠΌΡΡΠ°ΡΡΠΉ, Π·Π½Π°ΠΉΠ΄Π΅Π½ΠΈΡ
Π² XRCC1, TP53 ΡΠ° DPYD, Π·Π³ΡΠ΄Π½ΠΎ Π· Π΄Π°Π½ΠΈΠΌΠΈ ΡΠ½ΡΠΈΡ
ΠΊΠ»ΡΠ½ΡΡΠ½ΠΈΡ
Π²ΠΈΠΏΡΠΎΠ±ΡΠ²Π°Π½Ρ, ΠΌΠΎΠΆΡΡΡ Π±ΡΡΠΈ ΠΏΠΎΠ²βΡΠ·Π°Π½Ρ Π· ΠΏΡΠ΄Π²ΠΈΡΠ΅Π½ΠΎΡ ΡΡΡΠ»ΠΈΠ²ΡΡΡΡ Π΄ΠΎ ΠΏΠ»Π°ΡΠΈΠ½ΠΎΠ²ΠΈΡ
ΡΠ΅ΡΠ°ΠΏΡΠΉ ΡΠ° Π·ΠΌΠ΅Π½ΡΠ΅Π½ΠΎΡ ΡΡΡΠ»ΠΈΠ²ΡΡΡΡ Π΄ΠΎ 5-ΡΡΠΎΡΡΡΠ°ΡΠΈΠ»Ρ. ΠΠΈ ΡΠ°ΠΊΠΎΠΆ ΡΠ΄Π΅Π½ΡΠΈΡΡΠΊΡΠ²Π°Π»ΠΈ Π΄Π΅ΠΊΡΠ»ΡΠΊΠ° ΠΏΠΎΡΠ΅Π½ΡΡΠΉΠ½ΠΎ Π΄ΡΠ°ΠΉΠ²Π΅ΡΠ½ΠΈΡ
ΠΌΡΡΠ°ΡΡΠΉ, ΡΠΊΡ Π½Π° ΡΠ΅ΠΉ ΡΠ°Ρ Π½Π΅ ΠΌΠΎΠΆΡΡΡ Π±ΡΡΠΈ ΠΏΠΎΠ²βΡΠ·Π°Π½Ρ Π· ΡΠ΅ΡΠ°ΠΏΡΡΠΌΠΈ, Π½Π°ΠΏΡΠΈΠΊΠ»Π°Π΄ Π΄Π΅Π»Π΅ΡΡΡ Ρ CIRBP, Π·Π°ΠΌΡΠ½ΠΈ Π² BTG1, ERBB3, TCF7L2 ΡΠΎΡΠΎ. ΠΠΈΡΠ½ΠΎΠ²ΠΊΠΈ. ΠΠ°ΠΏΡΠΎΠΏΠΎΠ½ΠΎΠ²Π°Π½Π΅ Π΄ΠΎΡΠ»ΡΠ΄ΠΆΠ΅Π½Π½Ρ Π΄Π΅ΠΌΠΎΠ½ΡΡΡΡΡ ΠΏΠΎΡΠ΅Π½ΡΡΠΉΠ½Ρ ΠΊΠΎΡΠΈΡΠ½ΡΡΡΡ ΡΠ½ΡΠ΅Π³ΡΠΎΠ²Π°Π½ΠΎΠ³ΠΎ ΠΏΡΠ΄Ρ
ΠΎΠ΄Ρ Π΄ΠΎ NGS Π°Π½Π°Π»ΡΠ·Ρ Π΄Π°Π½ΠΈΡ
, Π² ΡΠΎΠΌΡ ΡΠΈΡΠ»Ρ Π°Π½Π°Π»ΡΠ·Ρ Π³Π΅ΡΠΌΡΠ½Π°ΡΠΈΠ²Π½ΠΈΡ
ΠΌΡΡΠ°ΡΡΠΉ ΡΠ° ΡΡΠ°Π½ΡΠΊΡΠΈΠΏΡΠΎΠΌΡ Ρ Π΄ΠΎΠ΄Π°ΡΠΎΠΊ Π΄ΠΎ Π²ΠΈΠΊΠΎΡΠΈΡΡΠ°Π½Π½Ρ ΠΎΠ½ΠΊΠΎΠ»ΠΎΠ³ΡΡΠ½ΠΈΡ
Π³Π΅Π½Π½ΠΈΡ
ΠΏΠ°Π½Π΅Π»Π΅ΠΉ Π°Π±ΠΎ Π΄Π°Π½ΠΈΡ
ΡΠ΅ΠΊΠ²Π΅Π½ΡΠ²Π°Π½Π½Ρ Π΅ΠΊΠ·ΠΎΠΌΡ.Π¦Π΅Π»Ρ. ΠΡΡΠ²Π»Π΅Π½ΠΈΠΈ ΠΊΠ»ΡΡΠ΅Π²ΡΡ
ΠΈΠ»ΠΈ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈ Π·Π½Π°ΡΠΈΠΌΡΡ
ΠΌΠΎΠ»Π΅ΠΊΡΠ»ΡΡΠ½ΡΡ
ΡΠΎΠ±ΡΡΠΈΠΉ Π΄Π»Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ° Ρ Π³Π΅ΠΏΠ°ΡΠΎΡΠ΅Π»Π»ΡΠ»ΡΡΠ½ΠΎΠΉ ΠΊΠ°ΡΡΠΈΠ½ΠΎΠΌΠΎΠΉ. ΠΠ΅ΡΠΎΠ΄Ρ. Π ΠΠ- ΠΈ ΡΠΊΠ·ΠΎΠΌΠ½ΠΎΠ΅ ΡΠ΅ΠΊΠ²Π΅Π½ΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΠΎΠΉ ΠΈ Π½ΠΎΡΠΌΠ°Π»ΡΠ½ΠΎΠΉ ΡΠΊΠ°Π½ΠΈ. ΠΡ ΠΏΡΠΎΠ°Π½Π½ΠΎΡΠΈΡΠΎΠ²Π°Π»ΠΈ Π½Π°ΠΉΠ΄Π΅Π½Π½ΡΠ΅ Π³Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ Π½Π°ΡΡΡΠ΅Π½ΠΈΡ, ΠΈΡΠΏΠΎΠ»ΡΠ·ΡΡ Π½Π΅ΡΠΊΠΎΠ»ΡΠΊΠΎ ΠΎΠ±ΡΠ΅Π΄ΠΎΡΡΡΠΏΠ½ΡΡ
Π±Π°Π· Π΄Π°Π½Π½ΡΡ
ΠΈ Π±ΠΈΠΎΠΈΠ½ΡΠΎΡΠΌΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΈΠ½ΡΡΡΡΠΌΠ΅Π½ΡΠΎΠ². Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. ΠΡ ΠΎΠΏΡΠ΅Π΄Π΅Π»ΠΈΠ»ΠΈ Π½Π΅ΡΠΊΠΎΠ»ΡΠΊΠΎ Π΄ΠΈΡΡΠ΅ΡΠ΅Π½ΡΠΈΠ°Π»ΡΠ½ΠΎ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
Π³Π΅Π½ΠΎΠ², ΡΠ²ΡΠ·Π°Π½Π½ΡΡ
Ρ ΠΊΠ»Π°ΡΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΡ
Π΅ΠΌΠΎΠΉ Π»Π΅ΡΠ΅Π½ΠΈΡ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠΌ ΡΠΎΡΠ°ΡΠ΅Π½ΠΈΠ±, Π° ΡΠ°ΠΊΠΆΠ΅ Π΄ΠΎΠΏΠΎΠ»Π½ΠΈΡΠ΅Π»ΡΠ½ΡΠ΅ ΠΏΡΡΠΈ ΠΏΠΎΡΠ΅Π½ΡΠΈΠ°Π»ΡΠ½ΠΎ ΠΏΠΎΠ΄Π΄Π°ΡΡΠΈΠ΅ΡΡ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ°ΠΌΠΈ, Π²ΠΊΠ»ΡΡΠ΅Π½Π½ΡΠΌΠΈ Π² ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΈΡΠΏΡΡΠ°Π½ΠΈΡ (ΠΡΠ»ΠΎΡΠΈΠ½ΠΈΠ±, ΠΠ°ΠΏΠ°ΡΠΈΠ½ΠΈΠ± ΠΈ Π’Π΅ΠΌΡΠΈΡΠΎΠ»ΠΈΠΌΡΡ). ΠΠ΅ΡΠΊΠΎΠ»ΡΠΊΠΎ Π³Π΅ΡΠΌΠΈΠ½Π°ΡΠΈΠ²Π½ΡΡ
ΠΌΡΡΠ°ΡΠΈΠΉ, Π½Π°ΠΉΠ΄Π΅Π½Π½ΡΡ
Π² XRCC1, TP53 ΠΈ DPYD, ΠΏΠΎ Π΄Π°Π½Π½ΡΠΌ ΠΈΠ· Π΄ΡΡΠ³ΠΈΡ
ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΈΡΠΏΡΡΠ°Π½ΠΈΠΉ, ΠΌΠΎΠ³ΡΡ Π±ΡΡΡ ΡΠ²ΡΠ·Π°Π½Ρ Ρ ΠΏΠΎΠ²ΡΡΠ΅Π½Π½ΠΎΠΉ ΡΡΠ²ΡΡΠ²ΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΡΡ ΠΊ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ°ΠΌ ΠΏΠ»Π°ΡΠΈΠ½Ρ ΠΈ ΠΏΠΎΠ½ΠΈΠΆΠ΅Π½Π½ΠΎΠΉ ΡΡΠ²ΡΡΠ²ΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΡΡ ΠΊ 5-ΡΡΠΎΡΡΡΠ°ΡΠΈΠ»Ρ. ΠΡ ΡΠ°ΠΊΠΆΠ΅ ΠΎΠΏΡΠ΅Π΄Π΅Π»ΠΈΠ»ΠΈ Π½Π΅ΡΠΊΠΎΠ»ΡΠΊΠΎ ΠΏΠΎΡΠ΅Π½ΡΠΈΠ°Π»ΡΠ½ΠΎ Π΄ΡΠ°ΠΉΠ²Π΅ΡΠ½ΡΡ
ΠΌΡΡΠ°ΡΠΈΠΉ Π² Π³Π΅Π½Π°Ρ
CIRBP, Π·Π°ΠΌΠ΅Π½Ρ Π² BTG1, ErbB3, TCF7L2 ΠΈ Π΄Ρ., ΠΊΠΎΡΠΎΡΡΠ΅ Π² Π½Π°ΡΡΠΎΡΡΠ΅Π΅ Π²ΡΠ΅ΠΌΡ Π½Π΅ ΡΠ²ΡΠ·Π°Π½Ρ Ρ ΡΠ΅ΡΠ°ΒΠΏΠΈΠ΅ΠΉ. ΠΡΠ²ΠΎΠ΄Ρ. ΠΠ°Π½Π½ΠΎΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ ΠΏΠΎΠΊΠ°Π·ΡΠ²Π°Π΅Ρ ΠΏΠΎΡΠ΅Π½ΡΠΈΠ°Π»ΡΠ½ΡΡ Π·Π½Π°ΡΠΈΠΌΠΎΡΡΡ ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠ½ΠΎΠ³ΠΎ ΠΏΠΎΠ΄Ρ
ΠΎΠ΄Π° ΠΊ Π°Π½Π°Π»ΠΈΠ·Ρ Π΄Π°Π½Π½ΡΡ
NGS, Π² ΡΠΎΠΌ ΡΠΈΡΠ»Π΅ Π°Π½Π°Π»ΠΈΠ·Π° Π³Π΅ΡΠΌΠΈΠ½Π°ΡΠΈΠ²Π½ΡΡ
ΠΌΡΡΠ°ΡΠΈΠΉ ΠΈ ΡΡΠ°Π½ΡΠΊΡΠΈΠΏΡΠΎΠΌΠ° Π² Π΄ΠΎΠΏΠΎΠ»Π½Π΅Π½ΠΈΠ΅ ΠΊ Π΄Π°Π½Π½ΡΠΌ ΠΈΠ· Π³Π΅Π½Π½ΡΡ
ΠΏΠ°Π½Π΅Π»Π΅ΠΉ ΠΈΠ»ΠΈ ΡΠ΅ΠΊΠ²Π΅Π½ΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΡΠΊΠ·ΠΎΠΌΠ°